Renata Oballa
Overview
Explore the profile of Renata Oballa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ding J, Gumpena R, Boily M, Caron A, Chong O, Cox J, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1116-1123.
PMID: 34267881
Both glycolate oxidase (GO) and lactate dehydrogenase A (LDHA) influence the endogenous synthesis of oxalate and are clinically validated targets for treatment of primary hyperoxaluria (PH). We investigated whether dual...
2.
Duong L, Wesolowski G, Leung P, Oballa R, Pickarski M
Mol Cancer Ther
. 2014 Sep;
13(12):2898-909.
PMID: 25249554
Cathepsin K (CatK) is essential for osteoclast-mediated bone resorption. CatK expression is also detected in breast cancer cells that metastasize to bone. Here, the CatK inhibitor L-235 dosed in prevention...
3.
Lyn R, Singaravelu R, Kargman S, OHara S, Chan H, Oballa R, et al.
Sci Rep
. 2014 Jul;
4:4549.
PMID: 25008545
Hepatitis C virus (HCV) replication is dependent on the formation of specialized membrane structures; however, the host factor requirements for the formation of these HCV complexes remain unclear. Herein, we...
4.
Leclerc J, Falgueyret J, Girardin M, Guay J, Guiral S, Huang Z, et al.
Bioorg Med Chem Lett
. 2011 Sep;
21(21):6505-9.
PMID: 21924609
It has been demonstrated that once-a-day dosing of systemically-distributed SCD inhibitors leads to adverse events in eye and skin. Herein, we describe our efforts to convert a novel class of...
5.
Ramtohul Y, Powell D, Leclerc J, Leger S, Oballa R, Black C, et al.
Bioorg Med Chem Lett
. 2011 Aug;
21(19):5692-6.
PMID: 21871798
Optimization of a lead thiazole amide MF-152 led to the identification of potent bicyclic heteroaryl SCD1 inhibitors with good mouse pharmacokinetic profiles. In a view to target the liver for...
6.
Landry F, Chan C, Huang Z, Leclair G, Li C, Oballa R, et al.
J Lipid Res
. 2011 Jun;
52(8):1494-9.
PMID: 21642745
A positive correlation between stearoyl-CoA desaturase (SCD)1 expression and metabolic diseases has been reported in rodents and humans. These findings indicate that SCD1 is a promising therapeutic target for the...
7.
Isabel E, Powell D, Black W, Chan C, Crane S, Gordon R, et al.
Bioorg Med Chem Lett
. 2010 Nov;
21(1):479-83.
PMID: 21074991
Potent and orally bioavailable SCD inhibitors built on an azetidinyl pyridazine scaffold were identified. In a one-month gDIO mouse model of obesity, we demonstrated that there was no therapeutic index...
8.
Powell D, Ramtohul Y, Lebrun M, Oballa R, Bhat S, Falgueyret J, et al.
Bioorg Med Chem Lett
. 2010 Oct;
20(22):6366-9.
PMID: 20933412
A series of potent, benzimidazole-based SCD inhibitors which demonstrate selectivity for the hSCD1 enzyme over the hSCD5 isoform are described. The compounds possess suitable cellular activity and pharmacokinetic properties which...
9.
Ramtohul Y, Black C, Chan C, Crane S, Guay J, Guiral S, et al.
Bioorg Med Chem Lett
. 2010 Feb;
20(5):1593-7.
PMID: 20137926
Elevated stearoyl-CoA desaturase (SCD) activity has been linked to a number of metabolic disorders including obesity and type II diabetes. Compound 3j, a potent SCD inhibitor (human HepG2 IC(50)=1nM) was...
10.
Leger S, Black W, Deschenes D, Dolman S, Falgueyret J, Gagnon M, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(2):499-502.
PMID: 20004097
A series of stearoyl-CoA desaturase 1 (SCD1) inhibitors were developed. Investigations of enzyme potency and metabolism led to the identification of the thiadiazole-pyridazine derivative MF-438 as a potent SCD1 inhibitor....